Five Prime Therapeutics (FPRX) Poses Smaller Q4 Loss
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Five Prime Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results
February 26, 2019 4:05 PM ESTSignificant Pipeline Expansion and Strong Clinical Execution in 2018 Phase 3 FIGHT Registrational Trial in Gastric and GEJ Cancer Enrolling Phase 2 Cabiralizumab/Opdivo® (nivolumab) Trial in Pancreatic Cancer Enrolling Phase 1 Starts for FPA150, FPT155 and BMS-986258 Multiple Data Readouts in 2019
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--... More
